



A Toolkit for the Application of Placental-Fetal Molecular Biomarkers in Epidemiologic Studies of the Fetal Origins of Chronic Disease

Jennifer J. Adibi^{1,2} · Alex J. Layden^{1,2} · Qing Yin³ · Xiaoshuang Xun¹ · Shyamal Peddada³ · Rahel Birru¹

Accepted: 23 October 2020 / Published online: 28 December 2020
© Springer Nature Switzerland AG 2020

Abstract

Purpose of Review In this review, we provide essential background knowledge and an analytical framework for the application of placental-fetal molecular biomarkers in fetal origins chronic disease epidemiology. The widely available and highly quantitative placental hormone human chorionic gonadotropin (hCG) is used as an example. hCG is currently used for diagnosing fetal genetic disorders; yet, it can and should be expanded to understanding the fetal origins of chronic diseases. We provide justification and methods to do this.

Recent Findings Ten papers published in the last 5 years were identified with supportive findings relevant to the application of biomarkers of hCG in epidemiologic studies on the developmental origins of health and disease (DOHaD).

Summary There is increasing and consistent evidence that placental-fetal biomarkers may be highly informative in observational studies, as exemplified by hCG, with the correct approaches for measurement and data analysis.

Keywords hCG · Human chorionic gonadotropin · Fetal origins · Epidemiology · Placenta · Directed acyclic graphs

Introduction

The developmental origins of health and disease (DOHaD) is a biologic theory that is increasingly recognized as a public health challenge. The complex and chronic health disorders obesity (18–26%), asthma (8–16%), autism (1.7%), and polycystic ovarian syndrome (12%) are suspected to originate in the prenatal period [1]. The body of empirical evidence to elucidate mechanism and support causality in these associations is nascent.

Because randomization of exposure in pregnant women as a strategy to assess causality is not an option for ethical reasons, one alternative is to apply diverse and creative approaches within the framework of observational birth cohort studies. For example, changes can be measured at the molecular level early during the period of fetal organogenesis (< 12 weeks gestation). Molecules in maternal blood can be measured that are informative of the health and well-being of the early embryo, the fetus, and/or the placenta. These data can then be used to estimate and illuminate developmental time- and sex-specific associations between maternal exposures and fetal and child outcomes.

During the first trimester, the placenta generates necessary cytokines, growth factors, and hormones to support the pregnancy and the fetus. Many of these are secreted into maternal blood and circulate at fairly high concentrations. The placenta is of particular interest in the paradigm being presented here. Even though commonly assumed to be maternal tissue, the placenta is fetal, carrying the same genotype and the same sex as the baby. Given the exceedingly low and difficult to measure levels of molecules being secreted by the early embryo and fetus, the placenta can be an alternative and rich source of information. It is large in size and surface area

This article is part of the Topical Collection on *Reproductive and Perinatal Epidemiology*

✉ Jennifer J. Adibi
adibij@pitt.edu

¹ Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, USA

² Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh, 130 Desoto Street, 5132 Public Health, Pittsburgh, PA 15213, USA

³ Department of Biostatistics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, USA

relative to the early embryo, it is in more direct contact with maternal blood, and a variety of proteins are produced by the placenta in higher volumes and can be more easily measured in maternal circulation than fetal proteins [2, 3].

Measuring placental molecules in maternal circulation is already in widespread use for the sake of prenatal screening for fetal genetic defects. Serum screening is commonly used in prenatal care to measure fetal well-being within developmental windows in the late first trimester (10–14 weeks) and early second trimester (15–20 weeks) to estimate the risk of fetal Down's Syndrome, trisomy 18, and neural tube defects [4–6]. Five analytes most commonly examined are human chorionic gonadotropin (hCG), pregnancy-associated plasma protein isoform A (PAPP-A), inhibin-A (INHA), unconjugated estriol (uE3), and alpha fetoprotein (AFP). Since the initial implementation of these tests, follow-up studies have demonstrated their utility in estimating risks of obstetric outcomes including preeclampsia [7], preterm labor [8], and fetal growth restriction [9].

The topic of this review is to understand how existing serum screening data can be utilized in observational studies that investigate the developmental origins of health and disease. The data exist and can be used generally at no additional cost. There is a biologically plausible rationale to apply these data as biomarkers of fetal developmental milestones in utero that can have lasting consequences. There are caveats as well as technical and analytical issues to be considered when analyzing these data in the context of fetal origins epidemiology, which will be outlined.

In this short review, the example of hCG will be the focus, given the large accumulation of knowledge of this particular hormone. The following will be addressed: (1) relevant background on hCG, including mechanisms by which hCG offers information on fetal development; (2) recently published epidemiologic findings on associations between maternal hCG levels and child health outcomes as well as environmental exposures; and (3) analytical approaches to apply these biomarkers to epidemiologic studies. Finally, we will extend important lessons and concepts learned from studies of hCG to other types of placental circulating biomarkers and to a checklist to guide future applications of placental-fetal biomarkers in DOHaD research.

Biologic Background

Human Chorionic Gonadotropin Biology hCG is a glycoprotein hormone. The intact hCG molecule is a heterodimer that consists of alpha and beta subunits. The alpha and beta subunits are encoded by distinct mRNAs, chorionic gonadotropin alpha (*CGA*) and chorionic gonadotropin beta (*CGB*), respectively. *CGB* has 6 coding and noncoding isoforms which are located on Chromosome 19q13.3 [10]. The *CGA* gene is located on Chromosome 6q14.3

and is identical to the alpha subunit of other glycoprotein hormones including thyroid stimulating hormone (*TSHA*), luteinizing hormone (*LHA*), and follicle stimulating hormone (*FSHA*). The beta subunit confers biologic specificity [11].

hCG Tissue Source In pregnancy, hCG is produced predominantly by the differentiated placental cell type called the trophoblast [11, 12]. There is also minor production by undifferentiated trophoblasts, stem cells, and the fetal adrenals [11, 13–17]. The difference in maternal circulating levels of hCG corresponds to differences in the expression of hCG mRNAs and proteins in the placental tissue [3, 18, 19].

hCG General Function hCG has been implicated in almost every physiologic process in pregnancy including uterine quiescence, immune tolerance, angiogenesis, and parturition [20, 21]. These processes are indirectly relevant to fetal development by way of changing canonical placental functions. Canonical placental functions refer here to maternal-placental blood flow, delivery of nutrients to the fetus, protection from infection, and the timing of delivery [22]. These types of processes might explain the well-reported association of maternal hCG levels and birthweight [23, 24].

Fetal vs. Placental vs. Maternal Concentrations One reason a placental protein is particularly informative relates to the ratio of maternal serum levels of that hormone relative to levels within the fetus and the placenta. The fetus and the placenta are the locations where the biologic action of interest is taking place, from the perspective of fetal development. Measuring and comparing levels of placental and fetal hormones in maternal serum inform us about the following processes: hormone synthesis, secretion, transport across the placental and fetal membranes, or metabolism. Such comparison has been thoroughly investigated for hCG, in a study where hCG concentrations were measured in the first trimester and compared between maternal and fetal compartments, via maternal serum and coelomic fluid, from the cavity which surrounds the amniotic sac and houses the embryo [2]. The coelomic fluid concentrations of hCG- α were 160-fold higher than those in maternal serum, hCG- β levels were 32-fold higher, and intact hCG was 1.3-fold higher [2]. These types of data confirm that hCG production is the highest in close proximity to the developing fetus and embryo. On this basis, we theorize that variability in hCG levels in maternal serum likely reflect meaningful variability in fetal and placental levels.

hCG and Fetal Development hCG has been selected as a valuable prenatal screening analyte because of the difference in the distribution of hCG in women carrying euploid (normal) fetuses vs. women carrying fetuses with trisomy 12 (Down's Syndrome) [6, 25]. Down's Syndrome children

characteristically have intellectual disabilities; yet, a mechanistic connection between abnormal hCG and fetal brain development has not been established. There are published hypotheses that have not yet been pursued in epidemiologic studies. One idea is that placental hCG, as part of a larger pathway, contributes to the development of the fetal neocortex and explains language development [26]. Experimental models also show that embryonic neurons can alter hCG secretion [27]. It is also possible that the hCG and Down's Syndrome association is noncausal, and hCG is simply a reporter molecule of the genetic defect that is common in the fetus and the placenta.

hCG also plays a direct role in the development of the fetal reproductive tract. It was demonstrated in the 1970s that hCG can bind the luteinizing hormone chorionic gonadotropin receptor (LHCGR) in the male fetal gonad and stimulate the onset of steroidogenesis [28]. In cases where this binding did not occur due to mutations in the LHCGR, males were born with hypogonadism and pseudohermaphroditism [29, 30]. In fetal organs collected from first-trimester terminations, hCG levels were markedly higher in fetal gonads as compared to other tissues [31].

Epidemiologic Findings

Literature of the last 5 years was reviewed for the purposes of identifying papers that give insight into the concept and the practice of applying hCG in epidemiologic studies to understand the fetal origins of chronic disease. The results of this search are summarized in Table 1, which was structured to include the associations examined, hCG measures utilized, and analytical approach. Three of the 10 papers identified are from the Generation R Study, a large population-based cohort in Rotterdam (the Netherlands) which has measures of hCG throughout pregnancy. The Generation R papers both confirm previous knowledge of hCG in the context of a modern day European cohort and offer novel insight into sources of effect modification of hCG associations with outcomes such as fetal growth and maternal thyroid function. The general categories of papers summarized in Table 1 are (1) associations between hCG and child health outcomes and (2) associations with environmental exposures. Below, we summarize these findings, highlight sources of biologic and technical variability in hCG measurements that deserve careful handling in epidemiologic studies, and note some important considerations for future work.

Associations With Child Health Outcomes Several studies characterized hCG associations with child outcomes related to reproductive tract development. At this time, the only reports are on prenatal hCG and neonatal anogenital distance (AGD) and the risk of hypospadias and undescended testes (UDT) at birth. AGD is an anthropometric marker of

masculinization, whereby shorter AGD indicates antiandrogenic actions in utero and longer AGD indicates pro-androgenic actions [41]. AGD is considered a sensitive and specific marker of fetal endocrine disruption [42–44]. Research prior to our 5-year window reported that mothers who gave birth to boys with UDT had 20% lower hCG in the second trimester as compared to women who gave birth to noncryptorchid boys [45]. In summary, results of the literature review demonstrated that hCG was correlated with developmental outcomes in boys; there was a stronger role for hCG in the first trimester vs. later in pregnancy; hCG associations are dynamic and require specialized techniques to address gestational age variation; hCG levels are correlated with maternal thyroid function, and also with outcomes in 2 domains of the development: fetal brain and reproductive tract development. In future analyses, hCG may have value as an indicator of fetal reproductive tract development that can be exploited in birth cohort studies where there are opportunities to follow children through puberty and to the point at which fertility can be evaluated.

One study examined associations of hCG with child outcomes related to brain development. hCG levels were measured in women who gave birth to children with cerebral palsy, diagnosed before the age of 5, and compared to levels in women who did not (Table 1, Paper 8). Maternal thyroid hormone is critically important to normal fetal brain development in this early period before the fetus begins producing its own thyroid hormone. hCG is considered thyrotropic (can bind to thyroid receptors and stimulate thyroid function) [46, 47]. The Generation R study demonstrated a strong association of hCG with maternal thyroid hormones in the first trimester (Table 1, Paper 6) and also showed that first-trimester thyroid hormone was associated with child cognition and brain morphology at 8 years of age [48]. However, in that paper, they did not report the association of hCG and brain development and only state that it was evaluated as a potential confounder.

Outcomes which deserve further investigation in this field include brain development, childhood obesity or fat mass, asthma, diabetes, pediatric cancer, outcomes during the pubertal transition, polycystic ovarian syndrome, and fertility by way of sperm counts or ovarian reserve later into early adulthood.

Associations With Environmental Exposures Conveniently, hCG is used in vitro as a standard endpoint indicative of toxic effects on trophoblast differentiation and function. Hence, toxicology studies can be a tool to look for evidence of dose-response relationships of diverse exposures and hCG. Experimental studies have the advantage of randomized exposure and can therefore make statements on causality. They provide an important and useful basis from which to justify human biomarker studies. It cannot be assumed, however, that these dose-response relationships translate directly to human

Table 1 Summary of published papers of the last 5 years in support of placental hCG as an informative biomarker in the epidemiology of fetal origins of chronic disease

Paper	Year	First author (ref)		
1	2015	Koreevar [32]	<i>N</i> Population hCG, serum Gestational window Primary association Technical variability Biologic variability Effect modification Estimation method Main finding	8195 Generation R, Rotterdam, Netherlands Analyte in IU/L, MoM, z-score < 9 to > 25 weeks Gestational age at blood draw and circulating hCG Method of gestational age determination Gestational age at time of blood draw, smoking, BMI, parity, ethnicity, maternal age, fetal sex, placental weight, reflux, nausea, vomiting, fertility, twins Pregnancy complication Linear regression, ANOVA, plotted using restricted cubic splines Confirmation of hCG predictors in this population.
2	2015	Adibi [33]	<i>N</i> Population hCG, serum Gestational window Primary association Biologic variability Effect modification Estimation method Main finding	1,088,668 Genetic Disease Screening Program, California, USA Analyte in IU/mL, MoM 10–14, 15–20 weeks Fetal sex and circulating hCG Fetal sex Maternal weight, age, gestational age at time of blood draw Linear regression, additive interactions hCG was 11% higher in women carrying females in the first trimester. There were small fluctuations in the female/male mean hCG ratio by maternal weight, race, and age, and larger fluctuations by gestational age.
3	2015	Adibi [34]	<i>N</i> Population hCG, serum Gestational window Primary association Biologic variability Effect modification Estimation method Main finding	541 The Infant Development and Environment Study, 4 sites, US z-score 10–14, 15–20 weeks Maternal urinary phthalates and neonatal anogenital distance (AGD), mediated by placental hCG First-trimester maternal urinary phthalate metabolites Fetal sex Linear regression, additive interactions, total and controlled direct effects (mediation analysis) by structural transformation. Qualitative interactions by fetal sex with exposure, mediator, and outcome. Higher hCG was associated with longer AGD in females and shorter AGD in males. 52% of the MnBP effect and 25% of the MEHP effect on male AGD was attributed to hCG mediation, and 78% of the MBZP effect in females. This is the only evidence to date that hCG was associated with size of female genitalia.
4	2016	Schneuer [35]	<i>N</i> Population hCG, serum Gestational window Primary association Effect modification Estimation method Main finding	22,617 Two states in Australia: New South Wales, Western Australia hCG-beta, MoM 10 and 13 weeks gestation hCG and hypospadias and undescended testes Placental dysfunction, co-existing congenital anomalies Kruskal-Wallis test, chi-squared test, Wilcoxon rank sum, logistic regression No association
5	2016		<i>N</i>	7987

Table 1 (continued)

Paper	Year	First author (ref)		
		Barjaktarovic [24]	Population hCG, serum Gestational window Primary association Effect modification Estimation method Main finding	Generation R, Rotterdam, Netherlands z-scores, normalized by gestational age at blood draw 11–14 weeks Circulating hCG and fetal growth (repeat measures from 18 to 25 weeks gestation), birthweight, small for gestational age (SGA) Fetal sex Linear fixed, and linear mixed effects, and logistic regression with splines for hCG, Markov Chain Monte Carlo imputation for missing data. High hCG in the first trimester was associated with increased growth of female fetuses, and decreased growth of male fetuses.
6	2017	Korevaar [36]	<i>N</i> Population hCG, serum Gestational window Primary association Effect modification Estimation method Main finding	5435 Generation R, Rotterdam analyte in IU/L 9.6–17.6 weeks hCG and maternal thyroid function Maternal thyroid disorders, thyroid autoimmunity, BMI, sex, parity Regression with restricted cubic splines with 3–4 knots, Markov Chain Monte Carlo imputation for missing data. hCG was inversely associated with the risk of hypothyroxemia (low T4) and hyperthyroidism (high T4 of T3), but there was no association of hCG and hypothyroidism (high TSH, low T4). Thyroid peroxidase (TPOAb) did not modify the association.
7	2017	Adibi [37]	<i>N</i> Population hCG, placental tissue Gestational window Primary association Effect modification Estimation method Main finding	180 Columbia Children’s Environmental Health Center <i>CGA</i> mRNA, <i>PPARG</i> mRNA (transcription factor that regulates mRNA), absolute quantitation Third trimester to birth Maternal phthalates and placental gene expression Baby sex Linear regression, phthalates modeled as quartiles, additive interactions Of 8 candidate genes, <i>CGA</i> was the most strongly associated with maternal phthalates and association differed in direction by sex.
8	2018	Eskild [38]	<i>N</i> Population hCG, serum Gestational window Primary association Effect modification Estimation method Main finding	29,948 Norway, population study, 1992–1994 Analyte, IU/L 4–12 weeks, 13–27 weeks, 28–40 weeks hCG and risk of cerebral palsy (CP) up to 5 years of age Trimester of pregnancy Student’s <i>t</i> tests, logistic regression Women had 0.8 (95% CI 0.6, 1.1) lower odds of CP per log unit hCG in the first trimester, and a 1.4 (95% CI 0.9, 2.2) higher odds in the second trimester.
9	2019	Chen [39]	<i>N</i> Population hCG, serum Gestational window Primary association Estimation method Main finding	131 Prenatal Screening Center of Yuhang District Maternal and Child Health Hospital of Hangzhou City (China) hCG-beta, MoM 15–20 weeks and 5 days hCG and hypospadias (individual risk prediction) <i>t</i> -test, ROC and Youden Index, life cycle-like risk calculation

Table 1 (continued)

Paper	Year	First author (ref)		
10	2019	Peycelon [40]	<i>N</i>	Women who gave birth to boys with hypospadias had 1.5 higher hCG-beta than controls. There was higher sensitivity and specificity in detecting hypospadias when both hCG and alpha fetoprotein (AFP) were used.
			Population	1269
			hCG, serum	Paris Registry of Congenital Malformations
			Gestational window	hCG-beta, MoM
			Primary association	10–13 weeks gestation
			Adjustment	hCG and hypospadias, proximal and distal
			Estimation method	Small for gestational age and prematurity (“proxies for placental function”), maternal age
			Main finding	Quantile regression
				MoM was 0.5 (95% CI 0.2, 0.9) higher in women with proximal hypospadias vs. controls

pregnancy. Generally, in vitro studies lack the same contextual signals of human pregnancy, namely, fetal and maternal paracrine and endocrine signals. Tissue culture conditions are designed to mimic human physiology but nonetheless differ in important ways.

Endocrine-disrupting compounds which altered hCG in placental cells cultured in vitro include chlorpyrifos, a commonly used organophosphate pesticide that has also been associated with child brain development [49, 50]; triclosan, an antimicrobial agent used in pharmaceutical and personal care products [51]; bifenthrin, a pyrethroid pesticide [52]; tetrabromobisphenol A, a brominated flame retardant [53]; phthalates, components of plastic and personal care products [54, 55]; bisphenol A, an epoxy used in plastics and food packaging [56, 57]; the surfactant p-Nonylphenol [58, 59]; cigarette smoke [60]; polycyclic aromatic hydrocarbons which are components of smoke [61]; and diethylstilbestrol, the teratogenic xenoestrogen prescribed to pregnant women from 1938 to 1971 [62]. Placental cells in vitro dosed with stress hormones (oxytocin, arginine-vasopressin, prolactin) also cause higher release of hCG [63].

Across these studies, the toxic substances both caused increases and decreases in hCG. In some cases, the doses used were noncomparable to human exposure. It is likely the hCG mechanisms at work also differed by exposure. Therefore, it is not possible to collapse this knowledge to a prediction of an overall direction of expected effect, or even a clear distinction between adverse and nonadverse effects. However, this literature presented here is sufficiently robust to support hCG as a fruitful biomarker in human studies investigating the consequences of exposure to endocrine-disrupting compounds.

Despite this body of evidence, birth cohort studies have minimally reported associations of maternal endocrine-disrupting exposures with hCG. In the last 5 years, two papers were published from our group on maternal phthalates and

hCG (Table 1, Papers 3 and 7). Previously to the review period, it was reported that a small number of women who reported diethylstilbestrol (DES) exposure in utero had a slower rise of urinary hCG in the first 7 days after implantation of their embryos [64]. Because the DES exposure of the subject’s mother preceded the current pregnancy and the formation of her placenta, the finding here suggests that placental hCG expression could be determined partially through an intergenerational mechanism in the oocyte (exposed to DES at the time when it formed) turned into zygote (grand-daughter of the DES exposed) [65]. This slower rise of hCG was reported in the same cohort to be associated with high vs. low monobenzyl phthalate levels measured in the same pregnancy [66]. Finally, a landmark study conducted at the population level demonstrated that aggregate levels of hCG may serve as indicators of aggregate-level economic stressors related to unemployment [67].

Analytical Issues

Appropriately Identifying Confounders and Effect Modifiers

In the papers reviewed, there is a consistent strategy with regard to adjustment for confounders of hCG associations with child health outcomes and environmental exposures, such as race, body mass index, and age. In one paper, the authors adjusted for “placental function” by including in the model small for gestational age and preterm delivery (Table 1, Paper 10). This and other factors such as gestational age at birth or birthweight or other pregnancy complications could potentially introduce bias by adjusting for either a potential intermediate variable or a condition that could be downstream of the hypothesized exposure effect on fetal or placental development. This strategy should be avoided when estimating effects of early hCG levels on outcomes at birth or after birth.

Gestational age at the time of the blood draw is a significant source of variability in hCG levels. hCG production begins within hours of conception and concentrations in maternal serum rise steadily from 0 to 10 weeks gestation [64, 68]. At 10 weeks, levels of intact hCG and hCG- β begin decreasing while hCG- α levels continue to rise in maternal serum until the end of pregnancy [68, 69]. The gestational age dependencies are not linear within the two periods in which prenatal screening takes place and these nonlinearities should be properly accounted for in measurement and statistical modeling strategies [32, 33, 69, 70]. Gestational age at the time of blood draw is correlated with dynamic aspects of maternal physiology and also with fetal developmental processes. For this reason, it may operate as an important effect modifier.

Fetal sex is also an established source of variability in circulating levels of hCG. Levels are approximately 10% higher in women carrying female fetuses vs. women carrying male fetuses [33]. The difference first emerges at approximately 3 weeks after conception [71]. Female fetal levels were 17% higher than male levels at the beginning of the first-trimester screening window. They decreased to be 2% higher at the end, and then the female levels increased steadily relative to the male levels to be 19% higher by 20 weeks or the end of the second-trimester screening window [33]. This is a finding that might be illustrative of a developmental process in one sex or the other where hCG played a role. For this reason, fetal sex should also be considered as a potential confounder and/or effect modifier of exposure effects on hCG and hCG effects on child outcome.

Measurement and Acquisition of Data Maternal serum analytes including hCG are generally measured by high-throughput, antibody-based methods. hCG can also be measured in small batches in maternal serum and urine by enzyme-linked immunosorbent assay (ELISA) using commercially available kits. Laboratories that conduct the high-throughput analysis include clinical laboratories within the hospital, research laboratories with proper certification within the institution, or commercial laboratories outside of the institutions. In 4 US states including California, these analyses are carried out in State Health Department Laboratories [72]. Absolute quantitation is achieved through the use of hCG standards and an absolute standard curve approach. In the case of hCG- β , the standards are maintained and distributed by the World Health Organization [73, 74]. The details of these methods are described elsewhere [75–77]. The form of hCG which is measured for serum screening purposes might be intact or total hCG or hCG- β depending on which assay is purchased.

In order to obtain these data for research purposes, there is often no additional human subject protection approval required if the original consent form asked permission to access the prenatal medical record. If not, a human subjects

protection modification should be submitted with the request for waiver given that the identifiability risks are the same as with the data already in use. The alternative would be to re-contact subjects and ask for informed consent.

Normalization of hCG for the Purpose of Causal Estimation

When working with a raw data set, there may be sources of technical variability such as antibody batch, drift over time in laboratory assays, sample shipment and storage, and error in how gestational age at time of blood draw was determined. The normalization of hCG for these factors is standard practice when used to estimate risk of Down's Syndrome at the individual level. The normalization procedure results in a quantity called the multiple of the median (MoM). The MoM was originally proposed in 1977 for the serum prenatal screening analyte AFP as a method to use a population-level association to establish clinically meaningful cut-offs at the individual level [78, 79]. It is a stepwise algorithm that includes regression techniques, likelihood ratio tests, and the Bayes Theorem. A detailed description is given elsewhere [80]. Despite the conceptual and statistical limitations of the MoM as have been pointed out [80], it generally works well, in combination with other markers, to detect a large proportion of affected fetuses. It has recently been proposed for use in the interpretation of child hormone levels [81] and could potentially be used for other placental biomarkers.

In addition to technical variability, the MoM is also used to normalize for biologic variability. The list of variables used in standard clinical algorithms to normalize hCG, generating the hCG MoM, includes maternal race, weight or BMI, smoking status, preconception diabetes status, and ovum donor status [70, 82]. MoM algorithms might be invaluable in a clinical setting where the goal is to predict individual level risk of Down's Syndrome, but may work against the epidemiologist who would like to estimate population risks. Normalization of the biomarker for sources of biologic variability can result in overadjustment [83].

In summary, normalization of placental biomarkers is necessary as part of the toolkit. However, normalization by the clinical variables currently used in the hCG MoM could create collider bias. The recommendation here is to base normalization on sources of technical variability and on gestational age at the time of the blood sample only and to adjust for other types of variability as confounders.

Estimation of Nonlinear Associations In the case of hormonally mediated mechanisms, such as the role of hCG, linear assumptions may fall short for the simple reason that hormonally mediated mechanisms characteristically have a low-dose effect (below the mean of exposure/mediator) that is distinct from the high-dose effect (above the mean of exposure/

mediator) [84, 85]. Relying on the linear model in this case might result in model misspecification and consequently incorrect estimates and conclusions. Other statistical techniques, such as splines, can and should be adopted to relax the linear assumption [86, 87].

Estimation of Direct vs. Indirect Pathways If hCG is being considered a component of the pathway between the exposure and the child outcome, then the analytical strategy could, in some fashion, include a comparison of the direct and indirect pathways. The direct pathway is assessing the effect of the exposure on the child outcome, not assuming that there are important intermediate variables. The indirect pathway in this case would assume that placental hCG is an important intermediate variable. Analysis of the indirect pathway assumes that hCG either interacted with the exposure to change the risk of the outcome or operated as a mediator of the effect of the exposure on fetal development leading to child outcome. There are multiple approaches to assessing the indirect pathway [88–90]. The first step is to clearly articulate why we suspect that placental hCG mediates a pathway that is distinct from and independent of the direct effect of exposure on outcome. The second step could be to estimate the total effect of the exposure and hormone and then to dissect the total effect into 4 components (i.e., the four-way decomposition method developed by VanderWeele) [89]. This methodology can be easily implemented via the STATA package, Med4way [91].

Future Directions

hCG is a well-studied and well-validated protein biomarker. In order to increase the value of this review for investigators interested in other types of placental–fetal biomarkers, we have included Supplemental Table 1 with a review of diverse biomarkers representative of extracellular vesicles called exosomes, epigenetics, proteomics, and metabolomics. These are new areas where the analytical issues necessary to measure and apply these biomarkers in a high-throughput, highly quantitative framework such as a longitudinal birth cohort study have not been as well worked out as hCG. In this mini-review, the literature was identified that is related these biomarkers to obstetric outcomes (preeclampsia, placenta previa, growth restriction, and gestational diabetes), due to a dearth of studies relating them to child health outcomes.

Furthermore, as a resource for investigators interested in applying placental biomarkers in their DOHaD research, we developed a checklist modeled after the STROBE and STROBE-ME checklists (Supplemental Table 2) [92, 93]. This covers essential steps in both developing a biomarker and also in applying an existing biomarker. This list can serve as a guide for journal reviewers and editors.

Conclusion

Placental circulating hCG as a biomarker in epidemiology is well-established with respect to a diverse set of maternal exposures and also with respect to dynamic processes in pregnancy. It is less well-established as a biomarker of long-term child health. We report here recent findings on associations of placental hCG with fetal brain and reproductive tract development. Provided here are technical and analytic details on the measurement and utilization of hCG measurements in epidemiologic studies, with the goal of providing an investigator toolkit to apply to other circulating placental biomarkers. The Supplement contains a mini-review of diverse types of placental biomarkers (exosomal, epigenetic, metabolome, and proteome) that hold promise for this field of research. An investigator checklist is presented to help formalize and standardize these approaches.

In studies of the influence of prenatal exposures on child health outcomes, maternal–placental–fetal mechanisms play an important and causal role. Studies that report only the direct effects of the prenatal exposure on childhood outcome ignoring the intermediate variables are omitting important information. Additionally, there are opportunities in this type of analysis for novel insight into the basic biology of pregnancy, the placenta, and the fetus. There are also opportunities to strengthen causal inferences regarding pregnancy exposures as important determinants (or not) of child health. Lastly, placental biomarkers could be a missing and essential key to reproducibility in epidemiologic findings. For example, investigators who have measured the same exposures and the same child outcomes at multiple sites could apply hCG data and the methods outlined here to their analysis. In doing this, they may find that there is a common indirect pathway between exposure and outcome through a mechanism involving placental hCG. This may be true even in cases where the direct effect of the exposure on the outcome was null or inconsistent across studies and sites.

This review provides an outline for others to plug in the same type of information for the prenatal screening analytes not reviewed here, namely, alpha fetoprotein, estriol, and inhibin-A which are also measured in prenatal serum screening programs. These could also serve as useful and valuable biomarkers of fetal endocrine disruption. Taken together, this would strengthen the toolkit for the epidemiologist who is developing specific and quantitative evidence of how exposures in early pregnancy can impact specific physiologic pathways related to fetal development. In some cases, one or more

of these proteins may prove to be highly associated and therefore highly informative.

The “low hanging fruit” has been plucked in terms identifying biomarkers of rare fetal genetic diseases, and now, we need a different toolkit to assess the utility of these biomarkers in identifying the early origins of chronic disease outcomes.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s40471-020-00258-x>.

Acknowledgments We thank Sona Saha and Robert Currier of the Genetic Disease Screening Program (GDSP) for their comments on this manuscript and support of our efforts to study hCG in the context of fetal origins epidemiology.

Funding Jennifer J. Adibi acknowledges her funding from the NIEHS (R01 ES029336-03) and the Pitt Public Health Department of Epidemiology. Alex Layden acknowledges funding 5TL1 TR001858-04 (PI: Kraemer).

Compliance with Ethical Standards

Conflict of Interest Jennifer J. Adibi reports grants from NIH, during the conduct of the study. The remaining authors have nothing to disclose related to the current work.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. Braun JM. Early-life exposure to EDCs: role in childhood obesity and neurodevelopment. *Nat Rev Endocrinol*. 2017;13(3):161–73. <https://doi.org/10.1038/nrendo.2016.186>.
2. Jauniaux E, Gulbis B. Fluid compartments of the embryonic environment. *Hum Reprod Update*. 2000;6(3):268–78. <https://doi.org/10.1093/humupd/6.3.268>.
3. Jauniaux E, Nicolaides KH, Nagy AM, Brizot M, Meuris S. Total amount of circulating human chorionic gonadotrophin alpha and beta subunits in first trimester trisomies 21 and 18. *J Endocrinol*. 1996;148(1):27–31. <https://doi.org/10.1677/joe.0.1480027>.
4. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down’s syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). *J Med Screen*. 2003;10(2):56–104. <https://doi.org/10.1258/096914103321824133>.
5. Dugoff L, Hobbins JC, Malone FD, Porter TF, Luthy D, Comstock CH, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (The FASTER Trial). *Am J Obstet Gynecol*. 2004;191(4):1446–51. <https://doi.org/10.1016/j.ajog.2004.06.052>.

6. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First-trimester or second-trimester screening, or both, for Down’s syndrome. *N Engl J Med*. 2005;353(19):2001–11. <https://doi.org/10.1056/NEJMoa043693>.
7. Tache V, Baer RJ, Currier RJ, Li CS, Towner D, Waetjen LE, et al. Population-based biomarker screening and the development of severe preeclampsia in California. *Am J Obstet Gynecol*. 2014;211(4):377 e1–8. <https://doi.org/10.1016/j.ajog.2014.03.026>.
8. Kirkegaard I, Uldbjerg N, Petersen OB, Topping N, Henriksen TB. PAPP-A, free beta-hCG, and early fetal growth identify two pathways leading to preterm delivery. *Prenat Diagn*. 2010;30(10):956–63. <https://doi.org/10.1002/pd.2593>.
9. Jelliffe-Pawlowski LL, Shaw GM, Currier RJ, Stevenson DK, Baer RJ, O’Brodoovich HM, et al. Association of early-preterm birth with abnormal levels of routinely collected first- and second-trimester biomarkers. *Am J Obstet Gynecol*. 2013;208(6):492 e1–11. <https://doi.org/10.1016/j.ajog.2013.02.012>.
10. Uusküla L, Rull K, Nagiraja L, Laan M. Methylation allelic polymorphism (MAP) in chorionic gonadotropin $\beta 5$ (CGB5) and its association with pregnancy success. *J Clin Endocrinol Metab*. 2011;96(1):E199–207 papers3://publication/doi/10.1210/jc.2010-1647.
11. Hussa RO. Biosynthesis of human chorionic gonadotropin. *Endocr Rev*. 1980;1(3):268–94. <https://doi.org/10.1210/edrv-1-3-268>.
12. Hoshina M, Boothby M, Hussa R, Pattillo R, Camel HM, Boime I. Linkage of human chorionic gonadotrophin and placental lactogen biosynthesis to trophoblast differentiation and tumorigenesis. *Placenta*. 1985;6(2):163–72. [https://doi.org/10.1016/s0143-4004\(85\)80066-7](https://doi.org/10.1016/s0143-4004(85)80066-7).
13. Complete and unidirectional conversion of human embryonic stem cells to trophoblast by BMP4, 2013.
14. Ezashi T, BPVL T, Roberts RM. Model systems for studying trophoblast differentiation from human pluripotent stem cells. *Cell Tissue Res*. 2012;349(3):809–24 papers3://publication/doi/10.1007/s00441-012-1371-2.
15. Genbacev O, Donne M, Kapidzic M, Gormley M, Lamb J, Gilmore J, et al. Establishment of human trophoblast progenitor cell lines from the chorion. *Stem cells (Dayton, Ohio)*. 2011;29(9):1427–36 papers3://publication/doi/10.1002/stem.686.
16. Yen SSC, Strauss JF, Barbieri RL. Yen & Jaffe’s reproductive endocrinology : physiology, pathophysiology, and clinical management. Seventh ed. Philadelphia: Elsevier/Saunders; 2014. p. 243–71.
17. Seron-Ferre M, Lawrence CC, Jaffe RB. Role of hCG in regulation of the fetal zone of the human fetal adrenal gland. *J Clin Endocrinol Metab*. 1978;46(5):834–7. <https://doi.org/10.1210/jcem-46-5-834>.
18. Brizot ML, Jauniaux E, McKie AT, Farzaneh F, Nicolaides KH. Placental expression of alpha and beta subunits of human chorionic gonadotrophin in early pregnancies with Down’s syndrome. *Hum Reprod*. 1995;10(9):2506–9. <https://doi.org/10.1093/oxfordjournals.humrep.a136331>.
19. Jauniaux E, Bao S, Eblen A, Li X, Lei ZM, Meuris S, et al. HCG concentration and receptor gene expression in placental tissue from trisomy 18 and 21. *Mol Hum Reprod*. 2000;6(1):5–10. <https://doi.org/10.1093/molehr/6.1.5>.
20. Licht P, Fluhr H, Neuwinger J, Wallwiener D, Wildt L. Is human chorionic gonadotropin directly involved in the regulation of human implantation? *Mol Cell Endocrinol*. 2007;269(1–2):85–92 papers3://publication/doi/10.1016/j.mce.2006.09.016.
21. Filicori M, Fazleabas AT, Huhtaniemi I, Licht P, Rao Ch V, Tesarik J, et al. Novel concepts of human chorionic gonadotropin: reproductive system interactions and potential in the management

- of infertility. *Fertil Steril*. 2005;84(2):275–84. <https://doi.org/10.1016/j.fertnstert.2005.02.033>.
22. Benirschke K, Kaufmann P. *Pathology of the human placenta*. 3rd ed. New York: Springer-Verlag; 1995.
 23. Krantz D, Goetzl L, Simpson JL, Thom E, Zachary J, Hallahan TW, et al. Association of extreme first-trimester free human chorionic gonadotropin- β , pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. *Am J Obstet Gynecol*. 2004;191(4):1452–8.
 24. Barjaktarovic M, Korevaar TIM, Jaddoe VWV, de Rijke YB, Visser TJ, Peeters RP, et al. Human chorionic gonadotropin (hCG) concentrations during the late first trimester are associated with fetal growth in a fetal sex-specific manner. *Eur J Epidemiol*. 2016;32(2):135–44. [papers3://publication/doi/10.1007/s10654-016-0201-3](https://doi.org/10.1007/s10654-016-0201-3).
 25. Canick JA, Kellner LH. First trimester screening for aneuploidy: serum biochemical markers. *Semin Perinatol*. 1999;23(5):359–68. [https://doi.org/10.1016/s0146-0005\(99\)80002-0](https://doi.org/10.1016/s0146-0005(99)80002-0).
 26. Montiel JF, Kaune H, Maliqueo M. Maternal-fetal unit interactions and eutherian neocortical development and evolution. *Front Neuroanat*. 2013;7:22. [papers3://publication/doi/10.3389/finana.2013.00022](https://doi.org/10.3389/finana.2013.00022).
 27. Shurtz-Swirski R, Simon RJ, Simon RJ, Cohen Y, Barnea ER. Human embryo modulates placental function in the first trimester; effects of neural tissues upon chorionic gonadotropin and progesterone secretion. *Placenta*. 1991;12(5):521–31. [papers3://publication/doi/10.1016/0303-6846\(91\)90007-0](https://doi.org/10.1016/0303-6846(91)90007-0).
 28. Huhtaniemi IT, Korenbrot CC, Jaffe RB. HCG binding and stimulation of testosterone biosynthesis in the human fetal testis. *J Clin Endocrinol Metab*. 1977;44(5):963–7. <https://doi.org/10.1210/jcem-44-5-963>.
 29. Kremer H, Kraaij R, Toledo SP, Post M, Fridman JB, Hayashida CY, et al. Male pseudohermaphroditism due to a homozygous missense mutation of the luteinizing hormone receptor gene. *Nat Genet*. 1995;9(2):160–4. <https://doi.org/10.1038/ng0295-160>.
 30. Potorac I, Rivero-Muller A, Trehan A, Kielbus M, Jozwiak K, Pralong F, et al. A vital region for human glycoprotein hormone trafficking revealed by an LHB mutation. *J Endocrinol*. 2016;231(3):197–207. <https://doi.org/10.1530/JOE-16-0384>.
 31. Huhtaniemi IT, Korenbrot CC, Jaffe RB. Content of chorionic gonadotropin in human fetal tissues. *J Clin Endocrinol Metab*. 1978;46(6):994–7. [papers3://publication/doi/10.1210/jcem-46-6-994](https://doi.org/10.1210/jcem-46-6-994).
 32. Korevaar TIM, Steegers EAP, Rijke YB, Schalekamp-Timmermans S, Visser WE, Hofman A, et al. Reference ranges and determinants of total hCG levels during pregnancy: the Generation R Study. *Eur J Epidemiol*. 2015;30(9):1057–66. [papers3://publication/doi/10.1007/s10654-015-0039-0](https://doi.org/10.1007/s10654-015-0039-0).
 33. Adibi JJ, Lee MK, Saha S, Boscardin WJ, Apfel A, Currier RJ. Fetal sex differences in human chorionic gonadotropin fluctuate by maternal race, age, weight and by gestational age. *J Dev Orig Health Dis*. 2015;6(6):493–500. <https://doi.org/10.1017/S2040174415001336>.
 34. Adibi JJ, Lee MK, Naimi AI, Barrett E, Nguyen RH, Sathyanarayana S, et al. Human chorionic gonadotropin partially mediates phthalate association with male and female anogenital distance. *J Clin Endocrinol Metab*. 2015;100(9):E1216–24. <https://doi.org/10.1210/jc.2015-2370>.
 35. Schneuer FJ, Bower C, Holland AJ, Tasevski V, Jamieson SE, Barker A, et al. Maternal first trimester serum levels of free-beta human chorionic gonadotropin and male genital anomalies. *Hum Reprod*. 2016;31(8):1895–903. <https://doi.org/10.1093/humrep/dew150>.
 36. Korevaar TIM, de Rijke YB, Chaker L, Medici M, Jaddoe VWV, Steegers EAP, et al. Stimulation of thyroid function by human chorionic gonadotropin during pregnancy: a risk factor for thyroid disease and a mechanism for known risk factors. *Thyroid*. 2017;27(3):440–50. <https://doi.org/10.1089/thy.2016.0527>.
 37. Adibi JJ, Buckley JP, Lee MK, Williams PL, Just AC, Zhao Y, et al. Maternal urinary phthalates and sex-specific placental mRNA levels in an urban birth cohort. *Environ Health*. 2017;16(1):35. <https://doi.org/10.1186/s12940-017-0241-5>.
 38. Eskild A, Monkerud L, Jukic AM, Åsvold BO, Lie KK. Maternal concentrations of human chorionic gonadotropin (hCG) and risk for cerebral palsy (CP) in the child. A case control study. *Eur J Obstet Gynecol Reprod Biol*. 2018;228:203–8. <https://doi.org/10.1016/j.ejogrb.2018.07.003>.
 39. Chen Y, Huang J, Mei J. A risk prediction model for fetal hypospadias by testing maternal serum AFP and free beta-hCG. *Clin Biochem*. 2019;69:21–5. <https://doi.org/10.1016/j.clinbiochem.2019.05.015>.
 40. Peycelon M, Lelong N, Carlier L, Monn FM, De Chalus A, Bonnard A, et al. Association of maternal first trimester serum levels of free beta human chorionic gonadotropin and hypospadias: a population based study. *J Urol*. 2019;101097JU00000000000000708. <https://doi.org/10.1097/JU.0000000000000708> **This paper and ref 41 and 102 are the supportive of the association reported earlier between circulating hCG and the risk of genital defects in male infants, and the general theory that hCG plays a role in masculinization programming.**
 41. Dean A, Sharpe RM. Clinical review: anogenital distance or digit length ratio as measures of fetal androgen exposure: relationship to male reproductive development and its disorders. *J Clin Endocrinol Metab*. 2013;98(6):2230–8. <https://doi.org/10.1210/jc.2012-4057>.
 42. Salazar-Martinez E, Romano-Riquer P, Yanez-Marquez E, Longnecker MP, Hernandez-Avila M. Anogenital distance in human male and female newborns: a descriptive, cross-sectional study. *Environ Health*. 2004;3(1):8–6.
 43. Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, et al. Decrease in anogenital distance among male infants with prenatal phthalate exposure. *Environ Health Perspect*. 2005;113(8):1056–61. <https://doi.org/10.1289/ehp.8100>.
 44. Barrett ES, Parlett LE, Redmon JB, Swan SH. Evidence for sexually dimorphic associations between maternal characteristics and anogenital distance, a marker of reproductive development. *Am J Epidemiol*. 2014;179(1):57–66. <https://doi.org/10.1093/aje/kwt220>.
 45. Chedane C, Puissant H, Weil D, Rouleau S, Coutant R. Association between altered placental human chorionic gonadotropin (hCG) production and the occurrence of cryptorchidism: a retrospective study. *BMC Pediatr*. 2014;14(1):191. <https://doi.org/10.1186/1471-2431-14-191>.
 46. Pekonen F, Alftan H, Stenman UH, Ylikorkala O. Human chorionic gonadotropin (hCG) and thyroid function in early human pregnancy: circadian variation and evidence for intrinsic thyrotropic activity of hCG. *J Clin Endocrinol Metab*. 1988;66(4):853–6. <https://doi.org/10.1210/jcem-66-4-853>.
 47. Pekonen F, Weintraub BD. Interaction of crude and pure chorionic gonadotropin with the thyrotropin receptor. *J Clin Endocrinol Metab*. 1980;50(2):280–5. <https://doi.org/10.1210/jcem-50-2-280>.
 48. Korevaar TI, Muetzel R, Medici M, Chaker L, Jaddoe VW, de Rijke YB, et al. Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood: a population-based prospective cohort study. *Lancet Diabetes Endocrinol*. 2016;4(1):35–43. [https://doi.org/10.1016/S2213-8587\(15\)00327-7](https://doi.org/10.1016/S2213-8587(15)00327-7).
 49. Ridano ME, Racca AC, Flores-Martín J, Camolotto SA, de Potas GM, Genti-Raimondi S, et al. Chlorpyrifos modifies the

- expression of genes involved in human placental function. *Reprod Toxicol.* 2012;33(3):331–8. <https://doi.org/10.1016/j.reprotox.2012.01.003>.
50. Ridano ME, Racca AC, Flores-Martin JB, Fretes R, Bandeira CL, Reyna L, et al. Impact of chlorpyrifos on human villous trophoblasts and chorionic villi. *Toxicol Appl Pharmacol.* 2017;329(C):26–39. <https://doi.org/10.1016/j.taap.2017.05.026>.
 51. Honkisz E, Zieba-Przybylska D, Wojtowicz AK. The effect of triclosan on hormone secretion and viability of human choriocarcinoma JEG-3 cells. *Reprod Toxicol* (Elmsford, NY). 2012;34(3):385–92. [papers3://publication/doi/10.1016/j.reprotox.2012.05.094](https://doi.org/10.1016/j.reprotox.2012.05.094).
 52. Zhao M, Zhang Y, Zhuang S, Zhang Q, Lu C, Liu W. Disruption of the hormonal network and the enantioselectivity of bifenthrin in trophoblast: maternal-fetal health risk of chiral pesticides. *Environ Sci Technol.* 2014;48(14):8109–16. <https://doi.org/10.1021/es501903b>.
 53. Honkisz E, Wojtowicz AK. The role of PPAR γ in TBBPA-mediated endocrine disrupting effects in human choriocarcinoma JEG-3 cells. *Mol Cell Biochem.* 2015;409(1):81–91. <https://doi.org/10.1007/s11010-015-2514-z>.
 54. Adibi JJ, Zhao Y, Zhan LV, Kapidzic M, LaRocque N, Koistinen H, et al. An investigation of the single and combined phthalate metabolite effects on human chorionic gonadotropin expression in placental cells. *Environ Health Perspect.* 2017;125(10):1–12. <https://doi.org/10.1289/EHP1539>.
 55. Shoaito H, Petit J, Chissey A, Auzeil N, Guibourdenche J, Gil S, et al. The role of peroxisome proliferator-activated receptor gamma (PPAR γ) in mono(2-ethylhexyl) phthalate (MEHP)-mediated cytotrophoblast differentiation. *Environ Health Perspect.* 2019;127(2):027003–15. <https://doi.org/10.1289/EHP3730>.
 56. Rajakumar C, Guan H, Langlois D, Cernea M, Yang K. Bisphenol A disrupts gene expression in human placental trophoblast cells. *Reprod Toxicol.* 2015;53:39–44. <https://doi.org/10.1016/j.reprotox.2015.03.001>.
 57. Morck TJ, Sorda G, Bechi N, Rasmussen BS, Nielsen JB, Ietta F, et al. Placental transport and in vitro effects of Bisphenol A. *Reprod Toxicol.* 2010;30(1):131–7. <https://doi.org/10.1016/j.reprotox.2010.02.007>.
 58. Bechi N, Ietta F, Romagnoli R, Focardi S, Corsi I, Buffi C, et al. Estrogen-like response to p-nonylphenol in human first trimester placenta and BeWo choriocarcinoma cells. *Toxicol Sci.* 2006;93(1):75–81. <https://doi.org/10.1093/toxsci/kfl043>.
 59. Bechi N, Ietta F, Romagnoli R, Jantra S, Cencini M, Galassi G, et al. Environmental levels of para-nonylphenol are able to affect cytokine secretion in human placenta. *Environ Health Perspect.* 2010;118(3):427–31. <https://doi.org/10.1289/ehp.0900882>.
 60. Kim CW, Lee HM, Lee K, Kim B, Lee MY, Choi KC. Effects of cigarette smoke extracts on cell cycle, cell migration and endocrine activity in human placental cells. *Reprod Toxicol.* 2017;73:8–19. <https://doi.org/10.1016/j.reprotox.2017.07.010>.
 61. Barnea ER, Shurtz-Swirski R. Modification of pulsatile human chorionic gonadotropin secretion in first trimester placental explants induced by polycyclic aromatic hydrocarbons. *Hum Reprod.* 1992;7(3):305–10. <https://doi.org/10.1093/oxfordjournals.humrep.a137640>.
 62. Bechi N, Sorda G, Spagnoletti A, Bhattacharjee J, Vieira Ferro EA, de Freitas BB, et al. Toxicity assessment on trophoblast cells for some environment polluting chemicals and 17 β -estradiol. *Toxicol in Vitro.* 2013;27(3):995–1000. <https://doi.org/10.1016/j.tiv.2013.01.013>.
 63. Tal J, Kaplan M, Sharf M, Barnea ER. Stress-related hormones affect human chorionic gonadotropin secretion from the early human placenta in vitro. *Hum Reprod.* 1991;6(6):766–9. <https://doi.org/10.1093/oxfordjournals.humrep.a137425>.
 64. Jukic AMZ, Weinberg CR, Baird DD, Wilcox AJ. The association of maternal factors with delayed implantation and the initial rise of urinary human chorionic gonadotropin. *Hum Reprod.* 2011;26(4):920–6. [papers3://publication/doi/10.1093/humrep/der009](https://doi.org/10.1093/humrep/der009).
 65. Escher J, Robotti S. Pregnancy drugs, fetal germline epigenome, and risks for next-generation pathology: a call to action. *Environ Mol Mutagen.* 2019;28:1–10. <https://doi.org/10.1002/em.22288>.
 66. Chin HB, Jukic AM, Wilcox AJ, Weinberg CR, Ferguson KK, Calafat AM, et al. Association of urinary concentrations of phthalate metabolites and bisphenol A with early pregnancy endpoints. *Environ Res.* 2019;168:254–60. <https://doi.org/10.1016/j.envres.2018.09.037>.
 67. Catalano R, Margerison-Zilko C, Goldman-Mellor S, Pearl M, Anderson E, Saxton K, et al. Natural selection in utero induced by mass layoffs: the hCG evidence. *Evol Appl.* 2012;5(8):796–805. <https://doi.org/10.1111/j.1752-4571.2012.00258.x>.
 68. Stenman UH, Tiitinen A, Alftan H, Valmu L. The classification, functions and clinical use of different isoforms of HCG. *Hum Reprod Update.* 2006;12(6):769–84. <https://doi.org/10.1093/humupd/dml029>.
 69. Nagy AM, Glinoe D, Picelli G, Delogne-Desnoeck J, Fleury B, Courte C, et al. Total amounts of circulating human chorionic gonadotropin alpha and beta subunits can be assessed throughout human pregnancy using immunoradiometric assays calibrated with the unaltered and thermally dissociated heterodimer. *J Endocrinol.* 1994;140(3):513–20. [papers3://publication/uuid/02D0CAC3-AC67-45F1-B174-C5E74C5E419D](https://doi.org/10.1093/oxfordjournals.eurpub.a020000).
 70. Vranken G, Reynolds T, Van Nueten J. Medians for second-trimester maternal serum markers: geographical differences and variation caused by median multiples-of-median equations. *J Clin Pathol.* 2006;59(6):639–44. <https://doi.org/10.1136/jcp.2005.034272>.
 71. Yaron Y, LeHAVI O, Orr-Urtreger A, Gull I, Lessing JB, Amit A, et al. Maternal serum HCG is higher in the presence of a female fetus as early as week 3 post-fertilization. *Human Reprod* (Oxford, England). 2002;17(2):485–9.
 72. Currier R, Wu N, Van Meter K, Goldman S, Lorey F, Flessel M. Integrated and first trimester prenatal screening in California: program implementation and patient choice for follow-up services. *Prenat Diagn.* 2012;32(11):1077–83. <https://doi.org/10.1002/pd.3961>.
 73. Palomaki GE, Lambert-Messerlian G. Down syndrome screening: suitability of a WHO 5 standardized total hCG assay. *Clin Biochem.* 2014;47(7–8):629–31. <https://doi.org/10.1016/j.clinbiochem.2014.01.013>.
 74. Sturgeon CM, Berger P, Bidart JM, Birken S, Burns C, Norman RJ, et al. Differences in recognition of the 1st WHO international reference reagents for hCG-related isoforms by diagnostic immunoassays for human chorionic gonadotropin. *Clin Chem.* 2009;55(8):1484–91. <https://doi.org/10.1373/clinchem.2009.124578>.
 75. Stenman UH. Pitfalls in hormone determinations. *Best Pract Res Clin Endocrinol Metab.* 2013;27(6):743–4. <https://doi.org/10.1016/j.beem.2013.10.006>.
 76. Stenman UH, Alftan H. Determination of human chorionic gonadotropin. *Best Pract Res Clin Endocrinol Metab.* 2013;27(6):783–93. <https://doi.org/10.1016/j.beem.2013.10.005>.
 77. Tecleab A, Lyashchenko AK, Rai AJ. Quad screen test, a multiplexed biomarker assay for prenatal screening to assess birth defects: the Columbia University experience using the Beckman Access2 immunoassay analyzer and Benetech PRA. *Methods Mol Biol.* 1885;2019:297–307. https://doi.org/10.1007/978-1-4939-8889-1_20.
 78. Wald NJ, Cuckle H, Brock JH, Peto R, Polani PE, Woodford FP. Maternal serum-alpha-fetoprotein measurement in antenatal

- screening for anencephaly and spina bifida in early pregnancy. Report of U.K. collaborative study on alpha-fetoprotein in relation to neural-tube defects. *Lancet*. 1977;1(8026):1323–32.
79. Tovey KC, Gerson M. Cut-off levels for maternal plasma alpha-fetoprotein in the diagnosis of neural tube defects: validation of the use of multiples of the normal median. *Br J Obstet Gynaecol*. 1979;86(7):507–15. <https://doi.org/10.1111/j.1471-0528.1979.tb10801.x>.
 80. Williams KL, Nix BA, Dunstan FD. Effect of screening algorithm, parameter values and median smoothing on patient-specific risk estimates for Down's syndrome screening. *Ann Clin Biochem*. 2000;37(Pt 2):165–73. <https://doi.org/10.1258/0004563001899168>.
 81. Zalas D, Reinehr T, Niedziela M, Borzikowsky C, Flader M, Simic-Schleicher G, et al. Multiples of median-transformed, normalized reference ranges of steroid profiling data independent of age, sex, and units. *Hormone Res Paediatr*. 2018;89(4):255–64. <https://doi.org/10.1159/000488028>.
 82. Reynolds TM, Vranken G, Van Nueten J. Weight correction of MoM values: which method? *J Clin Pathol*. 2006;59(7):753–8. <https://doi.org/10.1136/jcp.2005.034280>.
 83. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. *Epidemiology (Cambridge, Mass)*. 2009;20(4):488–95. <https://doi.org/10.1097/EDE.0b013e3181a819a1>.
 84. Li L, Andersen ME, Heber S, Zhang Q. Non-monotonic dose-response relationship in steroid hormone receptor-mediated gene expression. *J Mol Endocrinol*. 2007;38(5):569–85. <https://doi.org/10.1677/JME-07-0003>.
 85. Lee D-H, Jacobs DR Jr. Methodological issues in human studies of endocrine disrupting chemicals. *Rev Endocr Metab Disord*. 2016;16(4):289–97. <https://doi.org/10.1007/s1154-016-9340-9>.
 86. Prautzsch H, Boehm W, Paluszny M. Bézier and B-spline techniques. Mathematics and visualization. Berlin ; New York: Springer; 2002.
 87. Faman L, Ivanova A, Peddada SD. Linear mixed effects models under inequality constraints with applications. *PLoS One*. 2014;9(1):e84778. <https://doi.org/10.1371/journal.pone.0084778>.
 88. Marginal structural models for the estimation of direct and indirect effects, 2009.
 89. VanderWeele TJ. A unification of mediation and interaction: a 4-way decomposition. *Epidemiology (Cambridge, Mass)*. 2014;25(5):749–61. <https://doi.org/10.1097/EDE.000000000000121>.
 90. Naimi AI, Schnitzer ME, Moodie EE, Bodnar LM. Mediation analysis for health disparities research. *Am J Epidemiol*. 2016;184(4):315–24. <https://doi.org/10.1093/aje/kwv329>.
 91. Discacciati A, Bellavia A, Lee JJ, Mazumdar M, Valeri L. Med4way: a Stata command to investigate mediating and interactive mechanisms using the four-way effect decomposition. *Int J Epidemiol*. 2018;48:15–20. <https://doi.org/10.1093/ije/dyy236>.
 92. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *J Clin Epidemiol*. 2008;61(4):344–9.
 93. Gallo V, Egger M, McCormack V, Farmer PB, Ioannidis JP, Kirsch-Volders M, et al. STrengthening the Reporting of OBServational studies in Epidemiology–Molecular Epidemiology (STROBE-ME): an extension of the STROBE Statement. *Mutagenesis*. 2012;27(1):17–29.
 94. Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DR Jr, Lee DH, et al. Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. *Endocr Rev*. 2012;33(3):378–455. <https://doi.org/10.1210/er.2011-1050>.
 95. Jensen MS, Rebordosa C, Thulstrup AM, Toft G, Sorensen HT, Bonde JP, et al. Maternal use of acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk of cryptorchidism. *Epidemiology (Cambridge, Mass)*. 2010;21(6):779–85. <https://doi.org/10.1097/EDE.0b013e3181f20bed>.
 96. Snijder CA, Kortenkamp A, Steegers EA, Jaddoe VW, Hofman A, Hass U, et al. Intrauterine exposure to mild analgesics during pregnancy and the occurrence of cryptorchidism and hypospadias in the offspring: the Generation R Study. *Hum Reprod*. 2012;27(4):1191–201. <https://doi.org/10.1093/humrep/der474>.
 97. Huuskonen P, Amezaga MR, Bellingham M, Jones LH, Storvik M, Häkkinen M, et al. The human placental proteome is affected by maternal smoking. *Reprod Toxicol*. 2016;63:22–31. <https://doi.org/10.1016/j.reprotox.2016.05.009>.
 98. Van den Bergh BRH, van den Heuvel MI, Lahti M, Braeken M, de Rooij SR, Entringer S, et al. Prenatal developmental origins of behavior and mental health: the influence of maternal stress in pregnancy. *Neurosci Biobehav Rev*. 2017;1. <https://doi.org/10.1016/j.neubiorev.2017.07.003>.
 99. Lewis RM, Demmelmair H, Gaillard R, Godfrey KM, Hauguel-de Mouzon S, Huppertz B, et al. The placental exposome: placental determinants of fetal adiposity and postnatal body composition. *Ann Nutr Metab*. 2013;63(3):208–15. <https://doi.org/10.1159/000355222>.
 100. Shrier I, Platt RW. Reducing bias through directed acyclic graphs. *BMC Med Res Methodol*. 2008;8(1):70. <https://doi.org/10.1186/1471-2288-8-70>.
 101. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. *Epidemiology (Cambridge, Mass)*. 1999;10(1):37–48.
 102. Talge NM, Mudd LM, Sikorskii A, Basso O. United States birth weight reference corrected for implausible gestational age estimates. *Pediatrics*. 2014;133(5):844–53. <https://doi.org/10.1542/peds.2013-3285>.
 103. Bellavia A, Valeri L. Decomposition of the total effect in the presence of multiple mediators and interactions. *Am J Epidemiol*. 2017;187(6):1311–8.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.